Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406851 | 0.84 | MMP2 (0.34) | ALDH1A1OPRM1OPRD1MMP2MMP13 | |
| SCHEMBL6397621 | 0.83 | CHEK1 (0.35) | ALDH1A1OPRM1OPRD1CA12CA2 | |
| SCHEMBL6397626 | 0.83 | CHEK1 (0.35) | ALDH1A1OPRM1OPRD1CA12CA2 | |
| SCHEMBL6607831 | 0.81 | MMP2 (0.39) | ALDH1A1OPRM1OPRD1CA12CA2 | |
| SCHEMBL6607823 | 0.81 | MMP2 (0.39) | ALDH1A1OPRM1OPRD1CA12CA2 | |
| SCHEMBL6399628 | 0.73 | CA2 (0.36) | ALDH1A1CA12CA2MMP2 | |
| SCHEMBL6607282 | 0.73 | CYP2A6 (0.33) | CA12CA2MMP2MMP13TPSAB1 | |
| SCHEMBL6399624 | 0.73 | CA2 (0.36) | ALDH1A1CA12CA2MMP2 | |
| SCHEMBL6607137 | 0.73 | MMP2 (0.32) | ALDH1A1OPRM1OPRD1CA12CA2 | |
| SCHEMBL6607132 | 0.73 | MMP2 (0.32) | ALDH1A1OPRM1OPRD1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | ALDH1A1 945/4885OPRM1 1274/4885OPRD1 1405/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | ALDH1A1 356/4885OPRM1 1172/4885OPRD1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.